Left ventricular assist devices (LVADs) are increasingly common across the heart failure
population. Right ventricular failure (RVF) is a feared complication that can occur in the early …

Purpose Tolvaptan, a selective vasopressin type‐2 antagonist, has been shown to increase
serum sodium (Na) and urine output in hyponatremic left ventricular assist device (LVAD) …

Durable left ventricular assist device therapy has improved survival in patients with
advanced heart failure refractory to conventional medical therapy, although the readmission …

single-center study that the short-term use of tolvaptan following LVAD implantation is a safe
and effective therapy to augment diuresis and improve hyponatremia. Their analysis …

Risk stratification of post-heart transplant mortality in patients bridged with mechanical
circulatory supports. - Abstract - Europe PMC Sign in | Create an account https://orcid.org …